A designed molecule that attaches to both cyclophilin A and active RAS proteins blocks RAS signaling in cells with different RAS mutations by holding RAS in an inactive state.
Not yet evaluated
No evidence has been gathered for this claim yet.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
A designed molecule that attaches to both cyclophilin A and active RAS proteins blocks RAS signaling in cells with different RAS mutations by holding RAS in an inactive state.
See the technical phrasing
A bifunctional molecule that simultaneously binds cyclophilin A and active RAS proteins inhibits RAS signaling across multiple mutation variants by stabilizing RAS in its inactive conformation.
A molecule that attaches to both cyclophilin A and the RAS protein forces RAS into a shape that cannot activate downstream signals, blocking cancer-promoting pathways regardless of RAS mutations.
What the research says
Supports
1 study
Study: Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies